ArriVent Biopharma reports $305.4 million in cash and investments for Q3 2025
ArriVent Biopharma Inc. reported a net loss of $130.8 million for the nine months ended September 30, 2025, compared to a net loss of $59.9 million for the same period in 2024. Research and development expenses were $121.2 million, up from $58.8 million in 2024, including a $40 million one-time upfront payment for the in-licensing of ARR-217. General and administrative expenses reached $17.5 million, compared to $11.8 million in 2024. Net cash used in operations was $129.9 million for the period, up from $54.1 million the previous year. As of September 30, 2025, cash and investments totaled $305.4 million, expected to fund operations into mid-2027. Key business developments included FDA IND clearance for ARR-217, ongoing Phase 1 study in China, and the appointment of Brent S. Rice as Chief Commercial Officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571783-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.